Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.42 -0.08 (-0.46%)

Delayed Quote Updated: 10:02 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

30 31 32 33 34 35 36 37 Next >

Chevron, Amazon And Some Other Big Gainers From Friday ↗

August 01, 2022

U.S. stocks closed higher on Friday, with the Dow Jones jumping more than 300 points. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary ↗

July 29, 2022

Via Benzinga

Duchenne Gene Therapy Firm Sarepta Therapeutics' Earns 8% Price Target Hike From This Analyst ↗

July 29, 2022

Via Benzinga

Where Sarepta Therapeutics Stands With Analysts ↗

July 29, 2022

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Sarepta (SRPT) Stock Gains on FDA News ↗

July 29, 2022

Sarepta Therapeutics (SRPT) stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment.

Via InvestorPlace

Where Sarepta Therapeutics Stands With Analysts ↗

June 24, 2022

Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter:

Via Benzinga

Expert Ratings for Sarepta Therapeutics ↗

May 19, 2022

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:

Via Benzinga

Apple, Amazon And Some Other Big Stocks Recording Gains On Friday ↗

July 29, 2022

Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.4% of shares were redeemed by CCNB shareholders.

Via Benzinga

Exxon Mobil (XOM) Stock Pops on Record Profits ↗

July 29, 2022

Exxon Mobil (XOM) stock is rising on Friday following the release of its earnings report for the second quarter of the year.

Via InvestorPlace

CENN Stock Alert: Cenntro Invests in E-Cargo Designer ↗

July 29, 2022

Cenntro (CENN) stock is on the move Friday as investors react to news of the electric vehicle (EV) company acquiring a stake in Antric.

Via InvestorPlace

Sarepta Intents To Seek Accelerated Approval For Gene Therapy Candidate ↗

July 29, 2022

Sarepta Therapeutics (NASDAQ: SRPT) announced its intention to submit Biologics License Application (BLA) seeking accelerated approval for SRP-9001 to treat ambulant individuals with Duchenne muscular...

Via Benzinga

Sarepta Therapeutics: Q1 Earnings Insights ↗

May 04, 2022

Sarepta Therapeutics (NASDAQ:SRPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew ↗

July 12, 2022

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 07, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Investors Search for Clues in Economic Data, Recession Signals ↗

July 06, 2022

Stocks are extending this morning's quiet losses, as investors continue to keep an eye on signs of an oncoming recession.

Via Talk Markets

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial ↗

July 06, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗

June 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study ↗

June 23, 2022

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Sarepta Therapeutics's Earnings: A Preview ↗

May 03, 2022

Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

7 Potential Biotech Stocks Buyout Targets in 2022 ↗

April 21, 2022

Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.

Via InvestorPlace

Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating ↗

April 07, 2022

On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier.

Via Investor's Business Daily

Tough Slogging Ahead for Investors, Diversification is Important ↗

March 07, 2022

Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.

Via Talk Markets

Where Sarepta Therapeutics Stands With Analysts ↗

March 02, 2022

Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and...

Via Benzinga

Sarepta Therapeutics: Q4 Earnings Insights ↗

March 01, 2022

Sarepta Therapeutics (NASDAQ:SRPT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

< Previous 1 2

...

30 31 32 33 34 35 36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.